Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)

被引：0
|
作者：
N. L. Steele
J. A. Plumb
L. Vidal
J. Tjørnelund
P. Knoblauch
P. Buhl-Jensen
R. Molife
R. Brown
J. S. de Bono
T. R. J. Evans
机构：
[1] Beatson West of Scotland Cancer Centre,Centre for Oncology and Applied Pharmacology
[2] University of Glasgow,undefined
[3] Royal Marsden Hospital,undefined
[4] Topotarget,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 67卷
关键词：
Histone deacetylase; Phase-1 trial; Pharmacokinetics; Pharmacodynamics; Bioavailability;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：1273 / 1279
页数：6
相关论文
共 50 条
  • [41] A phase I/II study of belinostat (PXD101) in patients with unresectable hepatocelluar carcinoma
    Yeo, W.
    Lim, R.
    Ma, B. B.
    Hui, P.
    Chan, L.
    Mo, F. K.
    Yu, S. C.
    Ho, S. S.
    Koh, J.
    Chan, A. T.
    Goh, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [42] Activity of the histone deacetylase (HDAC) inhibitor PXD101 in preclinical studies and in a phase I study in patients with advanced haematological tumors.
    Gimsing, P
    Wu, F
    Qian, XZ
    Jeffers, M
    Knudsen, L
    Sehested, M
    Lichenstein, HS
    BLOOD, 2005, 106 (11) : 932A - 933A
  • [43] Growth inhibition of renal cancer cells by histone deacetylase inhibitors, suberoylanilide hydroxamic acid (SAHA) and PXD101
    Min, Gyeong Eun
    Hwang, Jung Jin
    Yoo, Changhee
    Kim, Mi-Joung
    Kim, Yong-Sook
    Song, Kanghyon
    Kim, Seong Cheol
    Kwon, Taek Min
    Park, Jong Yeon
    Ahn, Tai Young
    Kim, Choung-Soo
    JOURNAL OF UROLOGY, 2008, 179 (04): : 40 - 40
  • [44] A phase II trial of the histone deacetylase inhibitor Belinostat (PXD101) in patients with platinum resistant epithelial ovarian tumors and micropapillary/borderline (LMP) ovarian tumors. A trial of the PMH Phase II Consortium
    Mackay, Helen J.
    Hirte, Hal
    Covens, Al
    MacAlpine, Katrina
    Wang, Lisa
    Tsao, Ming
    Pan, James
    Zweibel, James
    Oza, Amit M.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3388S - 3388S
  • [45] A phase II trial of the histone deacetylase inhibitor belinostat (PXD101) in patients with platinum resistant epithelial ovarian tumors and micropapillary/borderline (LMP) ovarian tumors. A PMH phase II consortium trial
    Mackay, H.
    Hirte, H. W.
    Covens, A.
    MacAlpine, K.
    Wang, L.
    Tsao, M. S.
    Pan, J.
    Zwiebel, J. A.
    Oza, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [46] Belinostat (PXD101) resists UVB irradiation-induced cellular senescence and skin photoaging
    Jia, Hui-Jie
    Ge, Yuchen
    Xia, Jing
    Shi, Yi-ling
    Wang, Xiao-bo
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2022, 627 : 122 - 129
  • [47] The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage
    Feng, Rentian
    Oton, Ana
    Mapara, Markus Y.
    Anderson, Guelsuem
    Belani, Chandra
    Lentzsch, Suzanne
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 139 (03) : 385 - 397
  • [48] A phase 1 study of belinostat (PXD101) in combination with bortezomib in patients with advanced solid tumors and lymphoma
    O'Bryant, Cindy L.
    Leong, Stephen
    Camidge, D. Ross
    Gore, Lia
    Diab, Sami
    Gustafson, Dan L.
    Call, Justin
    Spratlin, Jennifer
    Zwiebel, James A.
    Eckhardt, S. Gail
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3384S - 3384S
  • [49] A phase 1 study of belinostat (PXD101) in combination with bortezomib in patients with advanced solid tumors or lymphoma
    Nallapareddy, Sujatha
    Leong, Stephen
    Camidge, Ross
    Gore, Lia
    Diab, Sami
    Messersmith, Wells
    Lewis, Karl
    Weekes, Colin
    Gustafson, Daniel
    Jimeno, Antonio
    Zwiebel, James
    -Delgado, Igor Espinoza
    Eckhardt, Gail
    O'Bryant, Cindy
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [50] Phase I study of belinostat (PXD101) plus azacitidine (AZC) in patients with advanced myeloid neoplasms
    Odenike, O.
    Green, M.
    Larson, R. A.
    Rich, E. S.
    Ott, J.
    Ratain, M. J.
    Stock, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345